Central nervous system relapse of acute promyelocytic leukemia treated by oral Venetoclax with Azacitidine achieved complete remission
Authors:
- 26 March 2022
- journal article
- letter
- Published by Springer Nature in Annals of Hematology
- Vol. 101 (8) , 1865-1867
Abstract
No abstract availableFunding Information
- Harbin Medical University (YKCX2018-15)
- Harbin Institute of Technology (No.JH20180176)
This publication has 5 references indexed in Scilit:
- Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case ReportFrontiers in Oncology, 2021
- Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood‐brain barrier be a disease “sanctuary” during venetoclax treatment?Clinical Case Reports, 2021
- Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaCancer Discovery, 2021
- Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective studyAnnals of Hematology, 2019
- Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvementHaematologica, 2019